InvestorsHub Logo
icon url

AAAtrades

10/03/18 6:51 PM

#8530 RE: newguy49 #8529

Why would you not want to partner with someone to make gel caps with MJ in them?

instead build a manufacturing facility from scratch and figure out how to make them on your own ?

the possiblities are endless, you can pretty much INFUSE CBD into everything

but yes these deals need to benefit both sides financially as well

dont forget Emerald can if needed supply HALF OF CANADAS MJ supply needs next year
icon url

guay

10/04/18 6:38 AM

#8533 RE: newguy49 #8529

Are you talking about the following key phrase in the latest news?

VivaCell is a wholly-owned subsidiary of Emerald Health Sciences, which has a 32% stake in Emerald Health Therapeutics Inc.


What are the possible advantages and disadvantages of these relationships and cooperations? (I wouldn't call them incestuous relationships because the companies mentioned act legally and fiscally independently of each other, or not?)

Are you afraid that too much unchecked money will "flow" from Emerald Therapeutics to Emerald Sciences? You could check that out in their annual report, or?
However, I estimate that the work VivaCell is doing on behalf of Emerald Health Therapeutics could have the following advantages, among others
1 - cheaper
2 - better to keep secret
3 - tax advantage as an external service
All IMHO I'm no expert just like you.
icon url

guay

10/04/18 7:49 AM

#8534 RE: newguy49 #8529

VivaCell is a subsidiary of Emerald Health Sciences, but Emerald Health Science and Emerald Health Therapeutics Inc. are two different companies that are related to each other through common ownership.


https://globenewswire.com/news-release/2018/08/30/1563574/0/en/Emerald-Health-Therapeutics-Reports-2nd-Quarter-2018-Financial-Results-and-Provides-Corporate-Update.html

See also:

Emerald Health Therapeutics Enters into Joint Venture with Emerald Health Bioceuticals, Inc. to Form Emerald Health Naturals; Appoints Gaetano Morello as CEO of Emerald Health Naturals
Apr 17 18

Emerald Health Therapeutics Inc. (EHT) launched a multi-pronged program to market and sell a proprietary, non-cannabis line of endocannabinoid-supporting nutritional products in Canadian grocery, natural health product, and pharmacy stores. EHT has entered into a 51:49 joint venture, to be called Emerald Health Naturals (EHN), with Emerald Health Bioceuticals, Inc. (EHB). EHN has secured exclusive Canadian marketing and sales rights to EHB's unique nutritional supplements, which use non-cannabis, non-psychoactive plant-based ingredients to provide potentially beneficial support to the body's endocannabinoid system. In this initiative, EHN has agreed to acquire the assets of GAB Innovations (GAB) and has granted non-exclusive sub-distribution rights to VANC Pharmaceuticals (VANC). Both GAB and VANC have established networks and a history of sales success in the natural health product and pharmacy channels. Gaetano Morello, ND, the founder of GAB, has been appointed CEO of EHN. EHT is leveraging multiple relationships to launch this initiative: Formed a joint venture with Emerald Health Bioceuticals. EHT will receive 51% of the shares of EHN in exchange for an investment of $5,000,000. EHB will receive 49% of the shares of EHN in exchange for granting the joint venture exclusive Canadian distribution rights with respect to EHB's product line. EHB developed and launched its over-the-counter product line of cannabis-free nutritional supplements in the U.S. The products feature PhytoCann-Complex™, EHB's proprietary formulation designed to support the body's endocannabinoid system and its central role in the orchestration, maintenance, and balance of health and wellbeing. The products include Endo Sleep™, Endo Inflame™, Endo Brain™, Endo Bliss™, Endo Calm™. EHB is a 70%-owned subsidiary of Emerald Health Sciences Inc. (Sciences), which also owns approximately 37% of the issued and outstanding shares of EHT. There will be no change in the share ownership of EHT by Sciences as a result of the joint venture. The joint venture with EHB was approved by the independent directors of EHT. Appointed Gaetano Morello, ND, as CEO of EHN. He serves on the Quality Assurance Committee for the College of Naturopathic Physicians of British Columbia and other health and medical panels.